Key result
iSTAT rapidly detects macrotroponin interference in Siemens Atellica samples, showing a ~57% negative bias.
Why the study?
Macrotroponins commonly confound hs-cTnI interpretation, but existing detection techniques tend to be slow and resource intensive.
Does the iSTAT hs-cTnI point of care assay rapidly detect macrotroponin interference when compared to the Siemens Atellica hs-cTnI assay?
Does the iSTAT hs-cTnI point of care assay rapidly detect macrotroponin interference when compared to the Siemens Atellica hs-cTnI assay?
Discordance between iSTAT and Siemens Atellica hs-cTnI assays can serve as a rapid and specific tool to detect macrotroponin interference in the central laboratory.
Answers are grounded in this paper and cite their sources.
iSTAT-Siemens discordance offers rapid macrotroponin screening in practice; provides first direct evidence but warrants validation before adoption.
• Techniques for macrotroponin detection tend to be slow and resource intensive. • A point of care hs-cTnI can be used by central laboratory as a comparative method. • Discordance between Atellica and iSTAT hs-cTnI rapidly detects many macrotroponins. Macrotroponins are increasingly recognized as the most common interference that confound interpretation of high sensitivity troponin I (hs-cTnI) results. Techniques for detection of macrotroponin presence tend to be slow and resource intensive. We evaluated the possibility of using a novel point of care hs-cTnI assay to rapidly distinguish samples with macrotroponin when original testing is performed on the Siemens Atellica hs-cTnI. 64 residual plasma specimens from 56 patients with low likelihood of macrotroponin (reference group) were retested on iSTAT hs-cTnI. A second group of 29 samples with previously confirmed macrotroponin I using selective IgG depletion were also re-tested on both assays (macrotroponin group). In the reference group samples, all except 4 showed close agreement between methods (median bias = −1.4% [90% CI −7.2%, +2.4%]) whereas macrotroponin-positive samples generally showed larger biases (median bias = −57% [90% CI −68%, −52%]). All 4 clearly discordant samples in the reference group showed low recovery after IgG depletion consistent with presence of macrotroponin. Despite the bias, 93% of macrotroponin-positive samples also produced iSTAT hs-TnI results above its sex-specific 99th percentiles. These preliminary data suggest analysing plasma on iSTAT hs-cTnI is a promising tool for rapid and specific macrotoponin detection in the central laboratory for investigation of clinically discordant troponin results produced by the Siemens Atellica platform.
No takes yet. Share an insight, caveat, or question.
Amir Karin (2026) studied this question. The iSTAT point-of-care assay rapidly detects macrotroponin interference in Siemens Atellica troponin samples, demonstrating a median bias of -57% compared to -1.4% in reference samples.
Synapse has enriched 10 related papers. Consider them for comparative context: